RT Journal Article
SR Electronic
T1 Evaluation of Vaccination Strategies for the metropolitan area of Madrid
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.29.21267009
DO 10.1101/2021.11.29.21267009
A1 Singh, David E.
A1 Lucerón, Carmen Olmedo
A1 Sánchez, Aurora Limia
A1 Guzman-Merino, Miguel
A1 Duran, Christian
A1 Delgado-Sanz, Concepción
A1 Gomez-Barroso, Diana
A1 Carretero, Jesus
A1 Marinescu, Maria-Cristina
YR 2021
UL http://medrxiv.org/content/early/2021/12/01/2021.11.29.21267009.abstract
AB Background This work analyses the impact of different vaccination strategies on the propagation of COVID-19 within the Madrid metropolitan area starting the 27th of December 2020 and ending in the Summer of 2021. The predictions are based on simulation using EpiGraph, an agent-based COVID-19 simulator.Methods We briefly summarize the different interconnected models of EpiGraph and then we provide a comprehensive description of the vaccination model. We evaluate different vaccination strategies, and we validate the simulator by comparing the simulation results with real data from the metropolitan area of Madrid during the third wave.Results We consider the different COVID-19 propagation scenarios on a social environment consisting of the ten largest cities in the Madrid metropolitan area, with 5 million individuals. The results show that the strategy that fares best is to vaccinate the elderly first with the two doses spaced 56 days apart; this approach reduces the final infection rate and the number of deaths by an additional 6% and 3% with respect to vaccinating the elderly first at the interval between doses recommended by the vaccine producer.Conclusion Results show that prioritizing the vaccination of young individuals would significantly increase the number of deaths. On the other hand, spacing out the first and second dose by 56 days would result in a slight reduction in the number of infections and deaths. The reason is the increase in the number of vaccinated individuals at any time during the simulation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been supported by the Carlos III Institute of Health under the project grant 2020/00183/001. The project of the Spanish Supercomputing Network (RES) under the grant BCV-2021-1-0011 and the European Union's Horizon 2020 JTI-EuroHPC research and innovation program under grant agreement No 956748. The role of all study sponsors was limited to financial support and did not imply participation of any kind in the study and collection, analysis, and interpretation of data, nor in the writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors